JP2013027391A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013027391A5 JP2013027391A5 JP2012171705A JP2012171705A JP2013027391A5 JP 2013027391 A5 JP2013027391 A5 JP 2013027391A5 JP 2012171705 A JP2012171705 A JP 2012171705A JP 2012171705 A JP2012171705 A JP 2012171705A JP 2013027391 A5 JP2013027391 A5 JP 2013027391A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- host cell
- polynucleotide
- nucleic acid
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 9
- 102000040430 polynucleotide Human genes 0.000 claims 9
- 108091033319 polynucleotide Proteins 0.000 claims 9
- 239000002157 polynucleotide Substances 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims 4
- 108010056852 Myostatin Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 230000002103 transcriptional effect Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims 2
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 claims 2
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims 2
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 2
- 108010023082 activin A Proteins 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73227005P | 2005-11-01 | 2005-11-01 | |
| US60/732,270 | 2005-11-01 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008539077A Division JP5349966B2 (ja) | 2005-11-01 | 2006-11-01 | 新規アクチビン受容体およびその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014136375A Division JP6072731B2 (ja) | 2005-11-01 | 2014-07-02 | 新規アクチビン受容体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013027391A JP2013027391A (ja) | 2013-02-07 |
| JP2013027391A5 true JP2013027391A5 (enExample) | 2014-05-01 |
Family
ID=37762538
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008539077A Expired - Fee Related JP5349966B2 (ja) | 2005-11-01 | 2006-11-01 | 新規アクチビン受容体およびその使用 |
| JP2012171705A Pending JP2013027391A (ja) | 2005-11-01 | 2012-08-02 | 新規アクチビン受容体およびその使用 |
| JP2014136375A Expired - Fee Related JP6072731B2 (ja) | 2005-11-01 | 2014-07-02 | 新規アクチビン受容体およびその使用 |
| JP2016155127A Pending JP2016187361A (ja) | 2005-11-01 | 2016-08-08 | 新規アクチビン受容体およびその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008539077A Expired - Fee Related JP5349966B2 (ja) | 2005-11-01 | 2006-11-01 | 新規アクチビン受容体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014136375A Expired - Fee Related JP6072731B2 (ja) | 2005-11-01 | 2014-07-02 | 新規アクチビン受容体およびその使用 |
| JP2016155127A Pending JP2016187361A (ja) | 2005-11-01 | 2016-08-08 | 新規アクチビン受容体およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US8067562B2 (enExample) |
| EP (1) | EP1943273B1 (enExample) |
| JP (4) | JP5349966B2 (enExample) |
| AT (1) | ATE554101T1 (enExample) |
| AU (1) | AU2006308614B2 (enExample) |
| CA (1) | CA2627200C (enExample) |
| ES (1) | ES2385581T3 (enExample) |
| WO (1) | WO2007053775A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130036378A (ko) | 2002-12-20 | 2013-04-11 | 암겐 인코포레이티드 | 미오스타틴을 저해하는 결합제 |
| ES2561048T3 (es) | 2004-07-23 | 2016-02-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| ME00380B (me) | 2005-11-23 | 2011-10-10 | Acceleron Pharma Inc | Amtagonisti aktivin-actriia i primjene za stimulaciju rasta kosti |
| ES2569365T3 (es) * | 2006-11-29 | 2016-05-10 | Nationwide Children's Hospital | Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular |
| CN104524548A (zh) | 2006-12-18 | 2015-04-22 | 阿塞勒隆制药公司 | 活化素-actrii拮抗剂及在提高红细胞水平中的用途 |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| US9526759B2 (en) | 2007-02-01 | 2016-12-27 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| KR101672156B1 (ko) | 2007-02-09 | 2016-11-02 | 악셀레론 파마 인코포레이티드 | 액티빈-ＡｃｔＲⅡＡ 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
| US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
| TW201718635A (zh) * | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| CN107412734A (zh) | 2007-09-18 | 2017-12-01 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| LT3750552T (lt) | 2008-08-14 | 2023-06-26 | Acceleron Pharma Inc. | Gdf gaudyklės |
| AU2013216639B2 (en) * | 2008-11-26 | 2016-05-05 | Amgen Inc. | Variants of activin IIB receptor polypeptides and uses thereof |
| KR20170105124A (ko) * | 2008-11-26 | 2017-09-18 | 암젠 인크 | 액티빈 ｉｉｂ 수용체 폴리펩타이드의 변이체 및 이의 용도 |
| CA2749544A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| EA027071B1 (ru) * | 2009-04-27 | 2017-06-30 | Новартис Аг | АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ |
| MX385318B (es) | 2009-06-08 | 2025-03-18 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
| JP2012529294A (ja) | 2009-06-12 | 2012-11-22 | アクセルロン ファーマ， インコーポレイテッド | 切断型ＡｃｔＲＩＩＢ−Ｆｃ融合タンパク質 |
| CA2770822C (en) * | 2009-08-13 | 2020-03-24 | Acceleron Pharma Inc. | Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels |
| US20110129469A1 (en) | 2009-11-03 | 2011-06-02 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
| EP2501400B1 (en) | 2009-11-17 | 2017-11-01 | Acceleron Pharma, Inc. | Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| SG187867A1 (en) | 2010-08-16 | 2013-03-28 | Amgen Inc | Antibodies that bind myostatin, compositions and methods |
| WO2012064771A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma, Inc. | Actriia binding agents and uses thereof |
| EP3520805B1 (en) | 2011-10-17 | 2021-03-10 | Acceleron Pharma Inc. | Compositions for treating myelofibrosis |
| CN104379159A (zh) | 2011-12-19 | 2015-02-25 | 安姆根公司 | 变体激活素受体多肽,单独或与化疗结合,及其用途 |
| CA2889209C (en) * | 2012-10-24 | 2023-08-22 | Celgene Corporation | Biomarker for use in treating anemia |
| RU2018145985A (ru) | 2012-11-02 | 2019-02-18 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| AU2014212014A1 (en) | 2013-02-01 | 2015-08-27 | Amgen Inc. | Administration of an anti-activin-A compound to a subject |
| ES2924479T3 (es) | 2013-04-08 | 2022-10-07 | Harvard College | Composiciones para rejuvenecer las células madre del músculo esquelético |
| JP6601687B2 (ja) * | 2014-03-31 | 2019-11-06 | 大日本住友製薬株式会社 | 進行性骨化性線維異形成症の予防剤及び治療剤 |
| MX388380B (es) | 2014-04-18 | 2025-03-19 | Acceleron Pharma Inc | Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes. |
| TN2016000553A1 (en) | 2014-06-13 | 2018-04-04 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| DK3227675T3 (da) | 2014-12-03 | 2023-05-30 | Celgene Corp | Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| DK3286206T3 (da) * | 2015-04-22 | 2021-05-03 | Biogen Ma Inc | Hidtil ukendte hybride actriib-ligand-trap-proteiner til behandling af muskelsvindsygdomme |
| IL305148A (en) * | 2015-09-15 | 2023-10-01 | Scholar Rock Inc | Anti-pro/hidden myostatin antibodies and their uses |
| EP3370754A4 (en) | 2015-11-04 | 2019-10-23 | Acceleron Pharma Inc. | METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE |
| CA3005975A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| CN116059320A (zh) | 2016-01-06 | 2023-05-05 | 哈佛学院校长同事会 | 使用gdf11的治疗防止体重增加、提高葡萄糖耐量并减轻脂肪肝 |
| RU2748278C2 (ru) | 2016-07-15 | 2021-05-21 | Акселерон Фарма Инк. | Композиции и способы лечения легочной гипертензии |
| EA201990226A1 (ru) | 2016-07-27 | 2019-08-30 | Акселерон Фарма Инк. | Способы и композиции для лечения миелофиброза |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| WO2018089715A1 (en) | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| KR20250059538A (ko) | 2017-11-09 | 2025-05-02 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| JP7510875B2 (ja) | 2018-01-12 | 2024-07-04 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉｂ型受容体変異体および同変異体を含む医薬組成物 |
| KR20250133994A (ko) | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| CN109293763B (zh) * | 2018-10-26 | 2021-10-26 | 中国农业科学院特产研究所 | 水貂激活素b蛋白及其制备与应用 |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| KR20230004515A (ko) | 2020-03-20 | 2023-01-06 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 ii 키메라 및 이의 사용 방법 |
| PE20260259A1 (es) * | 2023-03-09 | 2026-01-30 | Merck Sharp And Dohme Llc | Formulaciones que comprenden variantes polipeptidicas de actriia |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| US5750375A (en) | 1988-01-22 | 1998-05-12 | Zymogenetics, Inc. | Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions |
| US6162896A (en) * | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| US20050186593A1 (en) * | 1991-05-10 | 2005-08-25 | The Salk Institute For Biological Studies | Cloning and recombinant production of CRF receptor(s) |
| US5885794A (en) * | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
| US6153407A (en) | 1992-07-28 | 2000-11-28 | Beth Israel Deaconess Medical Center | Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics |
| US6465239B1 (en) | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
| US6607884B1 (en) | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
| ES2201076T3 (es) | 1993-03-19 | 2004-03-16 | The Johns Hopkins University School Of Medicine | Factor-8 de diferenciacion del crecimiento. |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| CA2187902A1 (en) * | 1994-04-29 | 1995-11-09 | Peter Ten Dijke | Morphogenic protein-specific cell surface receptors and uses therefor |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| EP1147413B1 (en) | 1999-01-21 | 2006-04-05 | Metamorphix, Inc. | Growth differentiation factor inhibitors and uses therefor |
| JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
| US6812339B1 (en) * | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| KR20130036378A (ko) | 2002-12-20 | 2013-04-11 | 암겐 인코포레이티드 | 미오스타틴을 저해하는 결합제 |
| JP2007531513A (ja) | 2003-11-13 | 2007-11-08 | ハンミ ファーム．インダストリー カンパニー リミテッド | 薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法 |
| US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
| ES2561048T3 (es) | 2004-07-23 | 2016-02-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| US20060034831A1 (en) | 2004-08-12 | 2006-02-16 | Wyeth | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
| CN101103045B (zh) | 2004-09-24 | 2015-11-25 | 安姆根有限公司 | 修饰的Fc分子 |
| KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물 |
| WO2006116415A2 (en) * | 2005-04-25 | 2006-11-02 | Litrex Corporation | Printhead maintenance station |
| US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
| TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
| US8318135B2 (en) | 2007-03-19 | 2012-11-27 | National Research Council Of Canada | Antagonist of ligands and uses thereof |
| CN107412734A (zh) | 2007-09-18 | 2017-12-01 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| LT3750552T (lt) | 2008-08-14 | 2023-06-26 | Acceleron Pharma Inc. | Gdf gaudyklės |
| KR20170105124A (ko) | 2008-11-26 | 2017-09-18 | 암젠 인크 | 액티빈 ｉｉｂ 수용체 폴리펩타이드의 변이체 및 이의 용도 |
| CA2749544A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| MX385318B (es) | 2009-06-08 | 2025-03-18 | Acceleron Pharma Inc | Metodos para aumentar adipocitos termogenicos. |
| US20120295814A1 (en) | 2010-01-08 | 2012-11-22 | The Brigham And Women's Hospital, Inc. | CA-125 Immune Complexes as Biomarkers of Ovarian Cancer |
| MX2011011596A (es) | 2010-03-31 | 2012-02-01 | Keryx Biopharmaceuticals Inc | Perifosina y capecitabina como un tratamiento combinado para cancer. |
| JP2012171705A (ja) * | 2011-02-17 | 2012-09-10 | Riso Kagaku Corp | 印刷装置 |
| JP6155653B2 (ja) * | 2013-01-17 | 2017-07-05 | 株式会社寺岡精工 | ラベルプリンタ |
-
2006
- 2006-10-31 US US11/590,962 patent/US8067562B2/en active Active
- 2006-11-01 AU AU2006308614A patent/AU2006308614B2/en not_active Ceased
- 2006-11-01 ES ES06827481T patent/ES2385581T3/es active Active
- 2006-11-01 WO PCT/US2006/043044 patent/WO2007053775A1/en not_active Ceased
- 2006-11-01 AT AT06827481T patent/ATE554101T1/de active
- 2006-11-01 EP EP06827481A patent/EP1943273B1/en active Active
- 2006-11-01 CA CA2627200A patent/CA2627200C/en not_active Expired - Fee Related
- 2006-11-01 JP JP2008539077A patent/JP5349966B2/ja not_active Expired - Fee Related
-
2011
- 2011-07-25 US US13/190,255 patent/US8614292B2/en active Active
-
2012
- 2012-08-02 JP JP2012171705A patent/JP2013027391A/ja active Pending
-
2013
- 2013-11-20 US US14/085,056 patent/US9284364B2/en active Active
-
2014
- 2014-07-02 JP JP2014136375A patent/JP6072731B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-03 US US15/014,889 patent/US20160152683A1/en not_active Abandoned
- 2016-08-08 JP JP2016155127A patent/JP2016187361A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013027391A5 (enExample) | ||
| JP2016187361A5 (enExample) | ||
| JP2012082206A5 (enExample) | ||
| JP2015521465A5 (enExample) | ||
| JP2016052315A5 (enExample) | ||
| JP2009539367A5 (enExample) | ||
| JP2017537622A5 (enExample) | ||
| JP2016034981A5 (enExample) | ||
| NZ592082A (en) | Promoters for recombinant viral expression | |
| JP2017538401A5 (enExample) | ||
| JP2012115277A5 (enExample) | ||
| FI3352776T3 (fi) | Htt-repressoreita ja niiden käyttötapoja | |
| JP2014508510A5 (enExample) | ||
| JP2016513669A5 (enExample) | ||
| JP2010518833A5 (enExample) | ||
| JP2010273685A5 (enExample) | ||
| JP2009513162A5 (enExample) | ||
| JP2011004753A5 (enExample) | ||
| JP2013502226A5 (enExample) | ||
| JP2018537089A5 (enExample) | ||
| JP2009528843A5 (enExample) | ||
| JP2017524380A5 (ja) | 腫瘍血管遮断剤であるポリペプチド、遺伝子、発現ベクター、腫瘍血管遮断剤の組成物、及び腫瘍血管遮断剤であるポリペプチドの調製方法 | |
| JP2015533791A5 (enExample) | ||
| JP2015520178A5 (enExample) | ||
| JP2018524019A5 (enExample) |